June 04, 2023

Clinical Trial Points to Treatment Advances for Glioma Patients for First Time in Decades

In the phase 3 INDIGO clinical trial co-led by Dana-Farber Cancer Institute, vorasidenib significantly prolonged progression free survival and delayed radiation and chemotherapy for patients with Grade 2 IDH-mutant glioma.

Dana-Farber

August 12, 2023

The Use of Tubular Retractors to Access Deep Brain Lesions

Johns Hopkins neurosurgeon Raj Mukherjee discusses the use of tubular retractors to access deep brain lesions.

Johns Hopkins Medicine

September 29, 2023

New Criteria to Assess Progression in Glioma Aims to Speed Discovery of New Medicines

In order to accurately assess the efficacy of novel therapies for brain tumors it is necessary to have reliable criteria to determine response or progression.

Dana-Farber

November 21, 2023

Focusing in on Medulloblastoma

Clinicians and scientists at Johns Hopkins All Children’s Hospital collaborated to identify the oncogene that is responsible for causing group three medulloblastomas in children.

Johns Hopkins Medicine

November 22, 2024

Global Adaptive Platform Trial for Glioblastoma to Evaluate Novel ATM Kinase Inhibitor

The Global Coalition for Adaptive Research announced an agreement to evaluate AZD1390, an ataxia telangiectasia mutant (ATM) kinase inhibitor, in its GBM AGILE trial. The AZD1390 arm will be assessed ...

The ASCO Post

November 21, 2024

Neuro-Oncology Guidelines Reveal How AI Could Improve Brain Cancer Diagnosis, Monitoring, and Treatment

Researchers have developed new clinical practice recommendations on the use of artificial intelligence (AI) methods to more accurately diagnose, monitor, and treat patients with brain cancer.

The ASCO Post

January 26, 2024

Focused Ultrasound Technology May Overcome Barrier to Brain Tumor Treatments

The blood-brain barrier protects the brain from many viruses, bacteria, and other harmful small molecules that could be circulating throughout the body. However, this same barrier prevents many cancer therapies from reaching brain tumors.

UCSF MedConnection

September 18, 2023

Dana-Farber Leads Adaptive, Efficient Multi-arm Phase 2 Clinical Trial for Glioblastoma

An innovative phase 2 clinical trial led by Dana-Farber Cancer Institute in collaboration with 10 major brain tumor centers around the country and designed to find new potential treatments for glioblastoma has reported initial results in the Journal of Clinical Oncology.

Dana-Farber

May 15, 2023

Cracking Glioblastoma’s Deadly Code: Research Focused on Improving Diagnosis and Genomics to Revolutionize Care

Even with growing awareness of the devastating effects of glioblastoma, the most common and aggressive form of brain cancer, treatment options remain limited and patients typically survive just 15-18 months beyond diagnosis. Researchers at the Miami Cancer Institute and Miami Neuroscience Institute, part of Baptist Health South Florida, are focusing their efforts to advance understanding of the disease and improve diagnostic, prognostic, and therapeutic outcomes.

Baptist Health South Florida